BRINK (BRain In Kidney Disease)
Funded by: National Institute on Aging
The goal of this study is to learn how common memory problems are in patients with and without chronic kidney disease (CKD), and the possible causes of these memory problems. This research could influence care and treatment to reduce the risk of memory loss in patients with CKD. There are no medications given as part of this study.
SHARP, Study of Heart and Renal Protection
Sponsored by: University of Oxford, UK
Funded by: Merck Schering Plough
SHARP is an international, double-blinded, placebo-controlled, randomized trial sponsored by the University of Oxford, UK. The Berman Center is the U.S. Regional Coordinating Center (RCC). The Berman Center is also a SHARP clinical site, enrolling participants locally.
SHARP will enroll approximately 9,000 patients with Chronic Kidney Disease (CKD) without coronary heart disease (CHD). Its purpose is to assess the effect of a cholesterol-lowering therapy for the reduction of cardiovascular (CV) events (non-fatal myocardial infarction or cardiac death, non-fatal or fatal stroke, or revascularization). Of the 9,000 participants, 3,000 are expected to be on dialysis and 6,000 pre-dialysis. The active treatment is a combination of simvastatin (20mg daily) and ezetimibe (10mg daily).